127. Frontotemporal lobar degeneration Clinical trials / Disease details

Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88

diseases per page:

Showing 1 to 10 of 90 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05742698 (ClinicalTrials.gov)	June 2023	23/11/2022	Nabilone for Agitation in Frontotemporal Dementia	Double Blind Crossover Clinical Trial of Nabilone for Agitation in Frontotemporal Dementia	Frontotemporal Dementia;Frontotemporal Dementia, Behavioral Variant;Primary Progressive Aphasia	Drug: Nabilone;Drug: Placebo	Simon Ducharme, MD	Alzheimer's Drug Discovery Foundation	Not yet recruiting	18 Years	N/A	All	45	Phase 3	NULL
2	NCT05683860 (ClinicalTrials.gov)	December 14, 2022	4/1/2023	Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral ...	A Multicenter, Open-label Extension (OLE) Study to Evaluate the Safety, Pharmacodynamics, and Clinic ...	ALS;FTD	Drug: WVE-004	Wave Life Sciences Ltd.	NULL	Enrolling by invitation	N/A	N/A	All	42	Phase 1/Phase 2	Netherlands
3	NCT05456503 (ClinicalTrials.gov)	September 19, 2022	8/7/2022	PET Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Using PI-2620	Imaging Tau Accumulation in FTLD and Atypical Alzheimer's Disease Using the PET Ligand PI-2620	Frontotemporal Lobar Degeneration;Alzheimer Disease;Cognitively Normal	Drug: FPI-2620	University of Pennsylvania	National Institutes of Health (NIH)	Recruiting	45 Years	N/A	All	54	Phase 3	United States
4	NCT05288842 (ClinicalTrials.gov)	September 6, 2022	27/7/2021	Tanycytes in Alzheimer's Disease and Frontotemporal Dementia	TANYCYTES' ROLE IN ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA: ARE THEY THE KEY TO WELL AGING?	Alzheimer Disease;Frontotemporal Dementia	Biological: Lumbar puncture;Biological: blood sample	University Hospital, Lille	European Research Council	Recruiting	40 Years	85 Years	All	102		France
5	EUCTR2021-005733-16-ES (EUCTR)	19/07/2022	12/05/2022	A 3 Part first-in-human study of DNL593 in healthy volunteers and patients with frontotemporal demen ...	A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Single Dose and Multiple Dose ...	Frontotemporal Dementia(FTD) MedDRA version: 21.1;Level: PT;Classification code 10068968;Term: Front ...	Product Name: DNL593 Sterile Lyophilisate Product Code: DNL593 INN or Proposed INN: N/A Other descriptiv ...	Denali Therapeutics Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 1;Phase 2	United States;Portugal;Serbia;Czechia;Spain;Turkey;Colombia;United Kingdom;Italy;France;Argentina;Br ...
6	NCT05315661 (ClinicalTrials.gov)	July 6, 2022	1/3/2022	The Safety and The Efficacy Evaluation of ET-STEM in Patients With Frontotemporal Dementia	Clinical Assessment on the Safety and Potential Efficacy of Mesenchymal Stem Cells Preconditioned Wi ...	Frontotemporal Dementia	Drug: ET-STEM	Samsung Medical Center	NULL	Recruiting	40 Years	85 Years	All	12	Phase 1	Korea, Republic of
7	NCT05184569 (ClinicalTrials.gov)	April 14, 2022	17/12/2021	Veri-T: A Trial of Verdiperstat in Patients With svPPA Due to TDP-43 Pathology	Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability, Pharmacokinetics, Pharm ...	Semantic Dementia	Drug: Verdiperstat	Peter Ljubenkov, MD	National Institutes of Health (NIH);Alzheimer's Association;National Institute on Aging (NIA)	Recruiting	18 Years	85 Years	All	64	Phase 1	United States
8	NCT05262023 (ClinicalTrials.gov)	February 1, 2022	1/2/2022	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in He ...	A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose ...	Frontotemporal Dementia	Drug: DNL593;Drug: Placebo	Denali Therapeutics Inc.	Takeda	Recruiting	18 Years	80 Years	All	106	Phase 1/Phase 2	Netherlands;Spain;Turkey;United Kingdom
9	EUCTR2021-002251-11-ES (EUCTR)	31/01/2022	08/10/2021	A clinical study to learn whether a new drug, TPN-101, is safe when given to patients with amyotroph ...	A Phase 2a Study of TPN-101 in Patients with C9ORF72 ALS/FTD (Amyotrophic Lateral Sclerosis and/or F ...	Amyotrophic lateral sclerosis or frontotemporal dementiadue to a genetic mutation called C9orf72 hex ...	Product Name: TPN-101 Product Code: TPN-101 INN or Proposed INN: CENSAVUDINE	Transposon Therapeutics, Inc	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	40	Phase 2	France;United States;Canada;Belgium;Spain;Netherlands;Germany;United Kingdom
10	EUCTR2020-005193-94-SE (EUCTR)	26/01/2022	12/10/2021	Phase 1b/2a Study of WVE-004 in Patients with C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) ...	A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 1b/2a Study of WVE-004 Administer ...	Amyotrophic Lateral Sclerosis and Frontotemporal Dementia MedDRA version: 21.1;Level: PT;Classificat ...	Product Code: WVE-004 INN or Proposed INN: not yet assigned Other descriptive name: Synthetic stereopu ...	Wave Life Sciences UK Limited	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	42	Phase 1;Phase 2	United States;Canada;Belgium;Ireland;Australia;Netherlands;Germany;United Kingdom;New Zealand;Sweden ...

First Previous1 2 3 4 5…9Next Last